Bimekizumab (BKZ) in AxSpA to Wk52
◦ sustained efficacy
◦ suppression of inflammation
◦ improvements in function and quality of life
◦ no new safety signals were observed
◦ consistent with the safety profileWk24 data
Baraliakos #L14 https://t.co/gk23g4vqQl #ACR22 @RheumNow
Links:
Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent S…
http://bit.ly/3O6C3od
14-11-2022